This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
For Inflectra® (infliximab) Prescribing Information for Northern Ireland click here
Adverse event reporting information can be found at the bottom of the page.

Support and Resources

Optimising treatment (TDM)

Optimising treatment (Biomarkers)

Therapeutic Drug Monitoring (TDM) and biomarkers such as faecal calprotection (FC) can be useful tools in helping to support clinical decision making to optimise treatment. Treatment optimisation can involve changing the dosing, infusion interval or stopping treatment. 

Please note that Inflectra/infliximab is not licensed for dose escalation in ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, paediatric ulcerative colitis or paediatric Crohn's disease. Inflectra/infliximab is licensed for dose escalation in rheumatoid arthritis and crohn's disease

What is TDM?

TDM is a measurement of serum drug concentrations and anti-drug antibodies (ADA) to allow more accurate adjustments of drug levels in an indiviudal patient.1-3

Figure adapted from Tracy D, et al. 2008.

TDM can provide clinical insight in either:

  • Primary non-response (PNR): lack of improvement in clinical signs and symptoms with induction therapy4
  • Secondary loss of response (LOR): loss of response during maintenance treatment after initial response to induction therapy4

Why are infliximab trough levels and ADA measured for TDM in IBD?

Montioring of infliximab trough levels is associated with improved clinical outcomes during induction therapy and maintenance therapy.5,6 Detectable ADA is associated with decreased serum concentration of infliximab7-9 and understanding ADA status is important to inform clinical decision making in induction and maintenance therapy.7,10,11

Why use TDM?

Personalised medicine can be particularly effective in infliximab treatment as patients can require different strategies to optimise their therapy.5  A personalised approach using TDM can lead to improved clinical outcomes and more effective use of infliximab, which has potential cost-savings.12-15  

Limited therapeutic options are available for patients with IBD16 and maximising anti-TNF drug persistence may help to avoid hospitalisation and surgery.17

​​​​​​​Applying TDM in clinical practice

Even minimal information can inform treatment strategy . The simple algorithm below can be used to interpret TDM results in clinical practice.18,19

Table created from Khanna R, et a;. 2013 and Bedtzen K, et al. 2019.
+ IS, Immunosuppression
* Please note that Inflectra/infliximab is not licensed for dose escalation in ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, paediatric ulcerative colitis or paediatric Crohn's disease.

Suggested infliximab threshold level for maintenance therapy ranges from >0.5 µg/ml to ≥10.1 µg/ml.20

Watch Dr Walter Reinisch discuss the benefits of using TDM in clinical practice:

Explore more

Optimising treatment with Inflectra

Learn more about TDM and biomarkers

Find out more
References
  1. Colombel J-F, et al. Inflamm Bowel Dis 2012. 18:349–358.
  2. Kingsley M, et al. Gastroenterol Hepatol 2016. 12:308–315.
  3. Tracey D, et al. Pharmacol Ther 2008. 117:244–279.
  4. Sprakes MB, et al. J Crohns Colitis 2012. 6:143–153.
  5. Adedokun O, et al. Gastroenterology 2014. 147:1296–1307.
  6. Bortlik M, et al. J Crohns Colitis 2013. 7:736–743.
  7. Ungar B, et al. Gut 2014. 63:1258–1264.
  8. Vermeire S, et al. Gut. 2007. 56:1226–1231.
  9. Van Stappen T, et al. Gut 2017. epub April 274.
  10. Roda G, et al. Clin Trans Gastroenterol 2016. 7:e135
  11. Golovics PA, et al. J Crohns Colitis 2017. 11:S4, ECCO abstract OP003.
  12. Vande Casteele N, et al. Gastroenterology 2015. 148:1320–1329.
  13. Steenholdt C, et al. Gut 2014. 63:919–927.
  14. Roblin X, et al. Journal of Market Access & Health Policy 2015. 3:292–29.
  15. Ding NS, et al. Aliment Pharmacol Ther 2016. 43:30-51.
  16. Velayos FS and Sandborn WJ. Curr Gastroenterol Hepatol 2007. 9:521–527.
  17. Pouillon L, et al. J Crohns Colitis 2017. 11:S4, ECCO abstract OP006.
  18. Khanna R, et al. Aliment Pharmacol Ther 2013. 38:447–459.
  19. Bendtzen K, et al. Scand J Gastroenterol 2009. 44:774–781.
  20. Mitrev N and Leong RW. Expert Opin Drug Saf 2017. 16:303–317.
PP-IFA-GBR-0513. September 2021

Quick Links

Learn about the mechanism of action of Infliximab. 

Find out more

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No